Mersana Therapeutics
ADC platform company betting on B7-H4: emiltatug ledadotin (Emi-Le) has Breakthrough designation in adenoid cystic carcinoma and activity in TNBC after TOP1 ADCs.
Emi-Le (XMT-1660, B7-H4, Dolasynthen platform) showed 23% ORR in TNBC previously treated with topoisomerase-1 ADCs and confirmed responses in ACC; FDA Breakthrough Therapy for ACC (May 2026) plus Fast Track designations. Mersana also pioneered immunosynthen STING-agonist ADCs (XMT-2056).
Pages like this
not linked directly; found by shared links- ProductPuxitatug samrotecan
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- IdeaRandomise the next line of treatment before the first one fails
Shares ADC sequencing, Acquired resistance to every therapy.
- TrialRAINFOL-01 (Rina-S)
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- IdeaUse SLFN11 status to decide which antibody-drug payload to give next
Shares ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
- ProductLuveltamab tazevibulin
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- CompanyCelldex Therapeutics
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- IdeaSequential multiple-assignment randomised trials to find the best order of ADCs
Shares ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- TermCross-resistance